The US patent office ruled Wednesday that hotly disputed patents on a revolutionary genome editing technology belong to the Broad Institute of Harvard and MIT, dealing a blow to the University of California’s effort to overturn those patents. In one sentence judgement by the Patent Trial and Appeal Board, three judges say key patent for what is known as CRISPR-Cas9, awarded to the broad beginning in 2014, are sufficiently different from patents applied for UC that they stand. The judge’s full 51-page decision explaining their reasoning stated that the Broad had persuaded them “that the parties patently distinct subject matter. “The ruling means that , in the eyes of patent office , breakthrough work by UC Biochemist Jennifer Doudna and her colleagues on CRISPR — an ancient bacterial immune system that they repurposed to easily and precisely edit DNA — was not so all-encompassing as to make later advances “obvious.” That is at odds with how much of the science world has viewed their work. Doudna and her chief collaborator, Emmanuelle Charpentier, won the $3 million Breakthrough Prize in the life sciences in 2015, the $500,000 Gruber Genetics Prize in 2015, and the $450,000 Japan Prize in 2017. The patent board said in its decision that the achievement of the Broad’s Feng Zhang in inventing a way to use CRISPR to edit the genomes of mouse and human cells “would not have been obvious” from the invention by Doudna and Charpentier “because one of ordinary skill in the art would not have reasonably expected a CRISPR-Cas9 system to be successful” in those higher-order cells.